Dominic Smethurst
About
In The Last Decade
Dominic Smethurst
28 papers receiving 536 citations
Peers
Comparison fields: 5 of 85
- Molecular Biology 285
- Oncology 242
- Pulmonary and Respiratory Medicine 105
- Immunology 88
- Cancer Research 73
Countries citing papers authored by Dominic Smethurst
This map shows the geographic impact of Dominic Smethurst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dominic Smethurst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dominic Smethurst more than expected).
Fields of papers citing papers by Dominic Smethurst
This network shows the impact of papers produced by Dominic Smethurst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dominic Smethurst. The network helps show where Dominic Smethurst may publish in the future.
Co-authorship network of co-authors of Dominic Smethurst
This figure shows the co-authorship network connecting the top 25 collaborators of Dominic Smethurst. A scholar is included among the top collaborators of Dominic Smethurst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dominic Smethurst. Dominic Smethurst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 13 | |
| 3 | 1 | |
| 4 | 92 | |
| 5 | A Phase I study of IMCgp100: durable responses with a novel first-in-class immunotherapy for advanced melanoma | 1 |
| 6 | 1 | |
| 7 | IMCgp100: a novel bispecific biologic for the treatment of malignant melanoma. | 2 |
| 8 | 53 | |
| 9 | 4 | |
| 10 | PRIMARY ANALYSIS AND BIOMARKER EVALUATION: RANDOMIZED PHASE IB/II STUDY OF RILOTUMUMAB (AMG 102) OR GANITUMAB (AMG 479) WITH PANITUMUMAB VERSUS PANITUMUMAB ALONE IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) | 0 |
| 11 | 31 | |
| 12 | 5 | |
| 13 | 23 | |
| 14 | 1 | |
| 15 | 0 | |
| 16 | 11 | |
| 17 | Atopic eczema. | 3 |
| 18 | 1 | |
| 19 | 40 | |
| 20 | 13 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.